Open access
Sep 2026
Re-Evaluating Multi-Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Combined Therapy in Colorectal Cancer: A Preclinical Study
It is shown that receptor tyrosine kinase inhibitors (RTKIs) designed to inhibit the overactivated FGFR and/or VEGFR signaling pathways exert an “off-target” effect on MDR proteins in colorectal cancer (CRC), thereby sensitizing CRC to certain chemotherapies.
S. Boichuk, T. Gessel, P. Dunaev et al.
· Cancers · 0 citations